The president's state visit comes amid tensions with carmaker Toyota over potential auto tariffs. Trump has repeatedly threatened Japanese and European carmakers with tariffs.Traderead more
Microsoft shares have gained 133% since November 2015, outperforming a tech "basket of unicorns" over that stretch.Technologyread more
Buybacks have gotten a bad rap from both Republicans and Democrats. But stocks would be trading at a massive discount without them.Marketsread more
The IRS is about to release a new draft of Form W-4, which will more closely reflect the changes stemming from the Tax Cuts and Jobs Act. For workers, that means they'll need...Personal Financeread more
The Mega Millions jackpot has spilled over $400 million. It would be the ninth largest winning since the game began in 2002.Personal Financeread more
When commercial real estate investor Manny Khoshbin spent $2.2 million on the fastest production car in the world, he had no idea it would very quickly also become the...Autosread more
Trump was speaking at a meeting of Japanese business leaders in Tokyo during his state visit to Japan on Saturday.Marketsread more
The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
The federal minimum wage has remained $7.25 per hour since 2009. But several states, and even some companies, have since taken matters into their own hands to pay employees a...Workread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
Martin Shkreli, the pharmaceuticals executive who gained public infamy by unapologetically hiking the price of a drug by more than 5,000 percent, on Monday begins jury selection for his trial on charges of securities fraud.
Shkreli, 34, is charged in Brooklyn, New York, federal court with ripping off a drug company he founded, Retrophin, for millions of dollars for the purposes of repaying investors whom he allegedly also defrauded at hedge funds he ran. The trial could last for up to six weeks.
The brash, social media and hip-hop-loving Brooklyn native, who has denied the allegations, was arrested on those charges in December 2015, months after garnering widespread scorn for raising the retail price of the drug Daraprim from $13.50 per pill to $750 per pill.
Another company that Shkreli founded, Turing Pharmaceuticals, earlier that year had purchased the drug, which is used to treat a parasitic condition found in pregnant women, infants and people with HIV.
The sky-high spike resonated with a public increasingly outraged by the cost of prescription medications. Shkreli quickly threw fuel on that fire by refusing to decrease the price of Daraprim.
Shkreli also reveled in using Twitter to insult his many critics, who included then-presidential candidate Hillary Clinton. Clinton's eventual opponent, Donald Trump, also joined in the public chorus denouncing Shkreli.
None of that scorn deterred Shkreli, who later smirked while refusing to testify about Daraprim's price during an appearance before a congressional committee.
Although it wasn't widely known at the time of the price hike, Shkreli was under federal criminal investigation for his tenure as CEO of Retrophin, the company he founded and ran before Turing. The company, echoed later by prosecutors, claimed that Shkreli had used publicly traded Retrophin like a personal piggy bank to pay back people who had invested in two Shkreli-run hedge funds with a series of stock transactions and consulting agreements.
Shkreli is accused of misrepresenting the assets of those funds to investors to hide the fact the funds were money-losers.
Prospective jurors on Monday are expected to be asked if they have any negative opinions about Shkreli based on widespread media attention he has received for the past two years.
That attention has included stories about his purchase, for a whopping $2 million, of a single-copy album by the hip-hop group Wu-Tang Clan, his heckling of Clinton outside her daughter's Manhattan apartment after she fainted last Sept. 11 after a 9/11 memorial event and his banning from Twitter for harassing a female journalist.
Shkreli is being represented by a high-powered legal team headed by Benjamin Brafman, whose past clients have included Dominique Strauss-Kahn, the International Monetary Fund chief who was accused of sexually assaulting a hotel maid.
Brafman, after being hired by Shkreli, told reporters that he had told his client that he needed to stop talking to journalists. That hasn't happened. Last week, he granted an interview to The Associated Press.
Shrekli also has continued livestreaming broadcasts online from his apartment, talking about investing, drug development, chess and more mundane matters to viewers.
He also, while free on $5 million bail, has spoken at several colleges, including Princeton, where he recently agreed to pay a senior $40,000 for solving a math proof for a problem Shkreli had posed.
Brafman last week said that offer, along with other monetary prizes posted by Shkreli, had not been paid, and that Shrekli was offering such rewards in an effort to remain in the public eye.
The lawyer said that Shkreli was essentially cash broke, although he claimed his client was worth tens of millions of dollars from Shkreli's ownership stake in Turing.
Brafman last week asked Judge Kiyo Matsumoto to reduce Shkreli's bail by $3 million so that the money could be used to reduce Shkreli's substantial tax liabilities, civil legal fees, and other debts related to both his tax issues and trial preparation.
The judge has yet to rule on that request. The $3 million that Shkreli hopes to free up is in an E-Trade account being used to secure his release bail.